Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
Frontiers in Pediatrics · 30.01.2025 · 13
DOI: 10.3389/fped.2025.1521425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 30.01.2025. Verfasst von Gilda M Portalatin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The sodium glucose co-transporter 2 (SGLT2) functions in the proximal tubule to reabsorb the bulk of filtered glucose. SGLT2 inhibitors have been developed to promote renal glucose excretion to improve glycemic control in diabetes. Regulatory guidance mandated adequately powered studies to detect increased cardiovascular risk from emerging hypoglycemic medications. This led to recognition of remarkable improvement in cardiovascular and kidney outcomes with SGLT2 inhibition. Moreover, cardiovascular and kidney benefits extend beyond patients with diabetes. The dramatic kidney benefits of SGLT2 inhibitors documented in CKD in adult patients underscores the need for pediatric nephrologists to familiarize themselves with SGLT2 inhibitor therapies. This review explores the currently available body of knowledge regarding the kidney protective effects of SGLT2 inhibitors in adults and mechanisms thought to contribute to improved kidney outcomes. The limited data for SGLT2i treatment in pediatric kidney disease are reviewed and highlight the need for randomized controlled trials of this drug class in pediatric kidney patients as has been done for pediatric diabetes. Dosing patterns for SGLT2 inhibitors from other pediatric settings are reviewed as well as guidance for initiating SGLT2 inhibition in young adults remaining in pediatric nephrology care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Vanderbilt University Medical Center, Nashville, TN, United States.
- Division of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, TN, United States.
- Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN, United States.
- Division of Pediatric Nephrology, Vanderbilt University Medical Center, Nashville, TN, United States.
Zitieren
APA
Portalatin, G. M., Hong-McAtee, I., Burgner, A. M., Gould, E. R., & Hunley, T. E. (2025). Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near. Frontiers in Pediatrics, 13. https://doi.org/10.3389/fped.2025.1521425
Vancouver
Portalatin GM, Hong-McAtee I, Burgner AM, Gould ER, Hunley TE. Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near. Frontiers in Pediatrics. 2025;13. doi:10.3389/fped.2025.1521425
BibTeX
@article{Portalatin2025,
author = {Portalatin, Gilda M and Hong-McAtee, Irene and Burgner, Anna M and Gould, Edward R and Hunley, Tracy E},
title = {Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near},
journal = {Frontiers in Pediatrics},
year = {2025},
volume = {13},
doi = {10.3389/fped.2025.1521425}
}
EUVIMED